Replies to post #9414 on Seelos Therapeutics Inc (SEEL)

[Dimitrios George]

<If APRI announced in Q4 a big partner or two for rest of Europe with 1) major upfront license fee revenues of $25M-$30M and 2) milestone payments totaling over time $100M or more, this stock would be up to $4-$5 in a jiffy. Yeah, that's dangling a big carrot, but quite feasible and reasonable.>

I agree that is a big carrot, but a likely one.

What interests me at this point is the complexity of the decision to get a partner. The company has stated that they have a lot of interest. Smaller pharmas probably want as much territory as they can get and may be willing to offer good upfront money and royalties. Larger pharmas, and the company probably wants a Pfizer or equal, will have some issues including existing competitors in online markets. So I see this as a decision complicated by the existing partnerships. The question will be which path offers the most "value" for at least the intermediate term. There is not a downside fortunately.